We have also previously demonstrated that treatment of platelets with the clinically used mood stabilizer valproic acid (VPA) is able to attenuate the release of sCD40L, due to the antiplatelet activity of this drug [20], which has also displayed neuroprotective effects in the context of HIV infection [21], [22] and improved BBB integrity in other models [23]. Here, CD40LG is linked to HIV infectious disease.